Back to Journals » Biologics: Targets and Therapy » Volume 6

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

Total article views   HTML views PDF downloads Totals
15,072 Dovepress* 11,217+ 2,522 13,739
PubMed Central* 3,855 1,180 5,035
Totals 15,072 3,702 18,774
*Since 25 September 2012
+Since July 2016

View citations on PubMed Central and Google Scholar